eIF2B Modulators That Counter p-eIF2α Translation Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with the integrated stress response (ISR) pathway, such as neurodegenerative diseases, leukodystrophies, cancers, inflammatory diseases, and metabolic diseases, are limited in effectively modulating the activity of eIF2B, leading to inadequate attenuation of the ISR.
Innovation Solution
Development of compounds that act as eIF2B modulators, specifically activators, represented by Formulas (I) and (II), to enhance eIF2B activity and attenuate the ISR pathway, thereby treating diseases like neurodegenerative diseases, leukodystrophies, cancers, inflammatory diseases, and metabolic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eIF2B activity is not sufficiently enhanced, then the ISR pathway remains active and disease symptoms persist, but increasing eIF2B activity may have unintended side effects on translation initiation
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to modulate eIF2B activity. These compounds bind to eIF2B and enhance its GEF activity toward phosphorylated eIF2α, selectively promoting the attenuation of ISR while maintaining control over the modulation process to avoid unwanted effects on general translation initiation
Solution Approach 2:
The patent employs compounds that change the kinetic parameters of eIF2B activity. By enhancing the rate of GDP/GTP exchange specifically in the context of phosphorylated eIF2α binding, the compounds increase eIF2B activity in a controlled manner that attenuates ISR without broadly affecting translation initiation across all conditions
2Reliability
If phosphorylated eIF2 binds tightly to eIF2B, then eIF2B activity is inhibited and translation is blocked, but this tight binding prevents effective modulation by activators
Solution Approach 1:
The patent employs activators that provide partial action by enhancing eIF2B activity rather than completely reversing the inhibition. The compounds increase the catalytic efficiency of eIF2B toward phosphorylated eIF2α, providing sufficient enhancement to attenuate ISR while maintaining the natural regulatory balance and avoiding over-activation that would disrupt normal translation control
Solution Approach 2:
The activators change kinetic parameters of the eIF2B-p-eIF2α interaction, specifically enhancing the rate of GDP release and GTP binding. This parameter enhancement allows the system to overcome the tight binding inhibition under stress conditions while preserving the ability of eIF2B to respond to physiological regulators
Data Source
AI summary
Provided herein are compounds, compositions, and methods useful for the modulation of elF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.